2-Acetylaminofluorene (2-AAF) was administered at Ievels of 0, 300 and 600 ppm in the diet for 28 days to female transgenic micc bearing the lacl genein a Iambda vector (Big Blue® mice). The Iambda vector was excised from liver DNA and packaged in vitro into bacteriophage particles which were allowed to infect E. coli bacteria, forming plaques on agar plates. Approximately 10 5 plaques wcre screened per animal for the appearance of a bluc colour, indicative of mutations in the lac/ gcnc which had resulted in an inactive gene product. Background mutation rate was 2.7 x 10-5 (pooled results of two animals, 8 mutant plaques/289 530 plaques). At 300 ppm in the diet, the rate of 3.5 X 10-5 (8/236 300) was not significantly increased over background. At 600 ppm in the dict, the rate increased approximately 3 fold to 7.7 x 10-5 (17 /221240). In comparison to the usual single or 5-day carcinogen exposure regimes, the 4-week exposure protocol allowed the use of much lower dose Ievels 00-1000 fold lower). Overt toxicity could thus be avoided. The daily doses used were somewhat higher than those required in 2-year carcinogenicity studies with 2·AAF.
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Transgenie animal technology is currently opening up new possibilities in biomedical research. One application of particular interest to toxicology is the devclopment of in vivo mutation assays as quantitative tools to assess thc mutagenic potency of chemicals. One such assay uscs transgenic mice bearing the /ac/ genc (ßig Bluc® mice). The genome of these mice has been manipulated such that every cell contains, stably integrated into the DNA, multiple tandem copies of a Iambda vector bearing the bacterial lac/ gene. lf the mice are exposed to mutagens, there is a small probability that a mutation will occur somewhere along the inserted sequence. Mutations that Iead to an inactive gene product (the lac repressor protein) are readily detected in host bacteria using a colour test (Kohler et al., 1990) .
Experiments with the lac/ transgenic mice to date have concentrated on short-term exposures ( 1-5 days), under which conditions extremely ]arge doses of known carcinogens, in the range of acute Iethai doscs, are necessary to producc a detectable incrcase in mutation frcqucncy in targct organs (Kohler ct al.. 1991b) . However, to bc useful for low-dose risk assessment. thc dctection Iimit of the assay would have to be improved. One possibility in this direction is a Ionger exposure period. We carricd out a subchronic (28-day) cxposure to the standard carcinogen 2-acetylaminofluorene (2-AAF). Results are compared to the quantitative dose-effect relationships in acute studies.
Materials and methods

Big Blue 'I( mouse assay princip/e
The genome of the mice contains multiple copies of a Iambda vector bcaring the lacl gene, stably inserted into an autosomal chromosome. If the mice are exposed to genotoxins, there is a small probability that a mutationwill occur somcwhere along the inserted sequence. Following carcinogen exposure, the Iambda vector bearing the target gcne is cxcised from the genomic DNA and packaged in vitro into infective Iambda bacteriophage particles. Thc particles are allowed to infect an excess of E. coli bacteria. On agar plates, plaques from infected bactcria show up as holcs against a lawn of uninfected bacteria. Mutations in the marker lacl gene are detected using a simple colour test: the lac/ gene encodes a protein that represses expression of lacZ, a bacterial gcne which codes for the enzyme ß-galactosidasc (ß-gal). If this lacl repressor is inactivated by a mutation, lacZ will be transcribed in the host bacteria and ß-gal activity expressed. ß-Gal activity is detected with the chromogenic substrate X-Gal, which makes a blue product upon cleavage. On the agar plates one thus finds isolated bluc plaqucs containing the mutated target gene amongst a vast majority of colourless plaques bearing the intact repressor. (For morc information on the lacl mutagencsis assay, see Kohler ct al.. 1990.) 
Animals and treatment
Six femalc 12-week-old C578Lj6 mice bearing thc /acl gcnc (Big Blue ~ mice) were obtained from Stratagene (Taconic Farms, Germantown, NY, USA). Animals wcre housed in macrolone cages on sawdust bedding. After 1 wcck's acclimatisation, the mice were randomly assigned to groups of two receiving pelleted Iab chow (Nafag Fecd 890, Gossau, Switzerland) containing 300 or 600 mgjkg 2-AAF (Fluka, Buchs, Switzerland; > 99% pure). Two control animals received pclleted chow lacking 2-AAF. Fccd consumption and weight gain were monitared twicc wcekly. After 28 days, the micc wcrc killed by heart puncture undcr ether anaesthesia, the livcr was removed. immediately frozen in liquid nitrogcn, and stored at '-20°C (for 2 weeks) until workup.
DNA isolation
A detailed protocol for the isolation of DNA and the mutation assay, based on established procedures as described in Sambrook et al. (Sambrook et al., 1989) , is available from Stratagene, La Jolla, CA, USA. The mcthods (all carried out undcr aseptic conditions) arc summarised bricfly below. A small slice of liver from the )arge lobe (approx. 150 mg) was homogenised briefly with 3 ml ice-cold douncing buffer ( 14 mM sodium phosphate, 20 mM EDT A, 140 mM NaCI, 5 mM KCI, pH 8.0) and incubated for 3 h at 50°C with an equal volume of proteinase K solution (2 mgjml proteinase K from Bochringer-Mannheim, Mannheim, Germany, 2% SOS, 100 mM EDTA, pH 7.5). Protein was removcd by two extractions with 6 ml phenol: chloroform (I : 1 ). Tbc upper aqueous layer was rcmoved with a wide-hore pipettc to prevent shearing the DNA. A final extraction with chloroform rcmoved most traces of phenol. The DNA was precipitated by slow addition of 2 volumes of room-temperaturc ethanol and thcn resuspended in 3 ml TE buffer ( 10 mM Tris · HCI. 1 mM EDTA. pH 7.5). DNA concentrations were measurcd photometrically (A lhll = 20 at 1 mgjml) and adjustcd to approx. I mgjml with TE buffcr. The morc concentratcd samples required over 1 weck to go fully into solution.
DNA packaging
Aliquots of 20 JLI DNA solution were transferred with wide-bore pipettc tips to Eppendorf tubes. Transpack ~ in vitro packaging extract components (Stratagenc) were thawed, mixcd as described in the kit and added to each liver DNA sample. Transpack ® is a patented mixture of Iambda phage coat proteins and enzymes, containing all components necessary to excise Iambda vectors from genomic DNA and construct viable phages. Sampies were incubated for 3 h at room temperature or 37°C. The packaging reactions were stopped by diluting the samples to I ml with SM buffer (Sambrook et al., 1989) and storing on ice. The Iambda vectors containing the bacterial /acl marker gene were now packaged into infectious bacteriophage particles.
Mutation assay
E. coli bacteria lacking thc ability to cleave methylated DNA (strain SCS-8, Stratagene) were freshly inoculated from an overnight culture and grown to mid log phase in liquid NZ-Y medium (0.5% Na Cl, 0.2% MgS0 4 • 7H 2 0, 0.5% yeast extract, 1% NZ amine, pH 7.0) supplemented with 0.25% maitose and 12.5 mM MgS0 4 • The bacterial pellet was spun down and suspended in 10 mM MgS0 4 to a concentration corresponding to an absorbance of 0.7 at 600 nm. Bacteria (2-ml aliquots) were mixed in 60-ml polyethylene tubes with 333 1-L l of bacteriophage suspension from the packaging reaction abovc (i.e., each packaging reaction was dividcd into thrce aliquots) and incubated at 37°C for 15 min. In the meantime, 1 g X-Gal (Staehelin, Basle) was dissolvcd in 3.5 ml dimethylformamide and addcd to 500 ml molten (52°C) top agar (NZ-Y medium with 0.7% agarose). Top agar (25 ml) was added to each The next day, plates were scored for mutant plaques (blue); the number of plaque-forming units (pfus) on the plate was estimatcd by manually counting plaques in represcntative sectors. After overnight incubation at 4°C, which intensifies the blue colour of X-Gal-positive plaques, platcs wcrc rccxamined for faint blue plaques. Plaques were confirmed by coring from thc plates, suspending in SM buffer containing chloroform and replating at low density with bacteria and X-Galon small NZ-Y petri dishes. About 10% of the putative mutants wcrc screened out by this process. The resulting mutation frequencies wcrc expresscd as nurober of blue plaques divided by the total nurober of plaques. Approximately 100 000 plaques from the liver were screened per animal for the appcarance of blue mutants.
Statistics
The confidence intervals for the mutation frequcncies were calculated on thc basis of a Poisson distribution (Werner, 1984) :
where p =:= real mutation frequency, k = number of mutants, n = total pfus counted, Fn.fl = uncertainty factors from 2-sided F-distribution Each line represents one animal.
* p = 0.02.
In our situation, with low mutation frequencies and total pfu counts below 500 000, the animalto-animal variation in mutation frequency was smaller than the mathematical uncertainty ·inher-ent in each frequency itself. For this reason, the data from the two animals in each dose group were pooled.
To compare the mutation rates of treated vs. control groups for significant differences, the statistical method 'comparison of Poisson rates' was used from the software package 'Statgraphics' (procedure as in Mansfield (1980) .
Results and discussion
The mutation frequencies observed in control and 2-AAF-treated animals are summarised in Table 1 . An approximately 3-fold increase in mutation frequency was observed in the liver of mice given 600 ppm 2-AAF in the diet for 1 month, whcreas the increase over background seen in the micc receiving 300 ppm was not significant. In principle, confidence Iimits for the mutation frequencies -and with this, the statistical signifi-TABLE 2 cance of a difference -is dependent on the nurober of plaques counted. In our case, for instancc, it would require the examination of a total of more than 10 million plaques ( > 2.5 million per animaO for the 30% increase in mutation frequency seen with the 300 ppm animals to become significant.
In comparison to the Iiterature reports (Myhr. 1991; Kohl er et al., 1991a,b; Hoorn et al., 1993) , our subchronic exposure regimen considerably increased the sensitivity of the assay. The fonner data are based on 1-5 doses of the carcinogens. The doses of carcinogen used and the mutation frequencies induced in the liver with acute and subchronic regimens, in comparison to the carcinogenic potencies of the test compounds, are summarised in Table 2 . As the data base is relatively small at this time, liver data from lacZ mice from Hazelton, Kensington, MD, USA (Myhr, 1991; Hoorn et al., 1993) The lowest dose giving rise to a significant effect is shown. a TD 511 is defined as the daily dose of a chemical (per kg body weight per day) that results in a 50% tumour incidence in Iabaratory animals after lifetime exposure (2 years in rats or mice). TD 50 values were from the database of Gold et al. (1991) . Where more than one carcinogenicity study with significant results was found in the database, the TD 50 value most closely matehing the conditions of the mutation assay was selected (i.e., data with mice, data from the same sex and organ as cxamined in the mutation assay). 11 lf more than one expression time was used following dosing, the most sensitive result is given here. animals after lifetime exposure. The TD 50 values were taken from the earcinogenie potency database of Gold and eoworkers (1991) . The 4-week treatment with 2-AAF showed a signifieant effect at a daily dose Ievel which was about 10-1000 times lower than in the aeute studies. If the dose of carcinogen is expressed as a multiple of the TD 50 value (eolumn 3), it becomes apparent that a daily dose of 2 x TD 50 sufficed to inducc a significant increase in mutation rate when given for 28 days.
No signs of 2-AAF-indueed toxicity were observed at the dose Ievels used in this study: both food consumption and weight gain were normal in the treated groups. However, in · the acute sturlies with chlorambucil (Hoorn et al., 1993) , ethyl-and methylnitrosourea (Myhr, 1991; Kohl er et al., 1991a) , doses lay in the acutely Iethai range (e.g., LD 50 of chlorambucil ~ 20 mgjkg). Taxicity can result in regenerative hyperplasia, whieh in turn can aceeierate the accumulation of mutations. Such results would be more difficult to use for extrapolation down to low-dose human exposure Ievels.
The inerease in sensitivity observed with the 4-week exposure is the result of a steady increase in the number of 'stem eells' (defined in this eontext as cells capable of dividing) that carry a lacl mutation. Stern cell division in a fully grown tissue is considered to result in one eell eommitted to differentiation and death, and another stem cell eapable of further divisions. DNA darnage ean give rise to mutations in both types of progeny cells. If the mutation is generated in the differentiated cell, its contribution to the mutation frequency determined in the DNA isolated from the whole tissue will be limited by the lifespan of this cell. If, on the other hand, the mutation is in the secondary stem cell, it will be passed on to all future progeny, and all subsequent divisions will result in an increase in mutation frequency until a steady state is reached between birth and death of the mutated differentiated cells of this lineage.
Specific mutations are rare· events. Therefore, the number of lac/-mutated stem cells will always be much smaller than the number of stem cells not mutated at this locus. The number of stem cells that can be recruited to undergo a particular 95 mutation remains essentially constant over the life-time of the animal; thus, the mutation frequency can increase linearly over time. This also means that additionally lengthening the treatment period would further increase the sensitivity of the assay.
Despite the reduction of the daily dose achieved by the Ionger exposure period, it is still necessary to give high doses of chemieals in order to induce measurable increases in mutation frequency in these transgenic mause mutation assays: 150 ppm 2-AAF in the diet for 2 years led to a 40% increase in liver tumour incidence in BALB/c mice (Littlefield et al., 1980) . Thus, with the 1-month exposure protocol, the assay with the transgenic mice was actually less sensitive than the long-term carcinogenicity bioassay. It is clear that further refinements of the assay are necessary. Refinements to the presently existing system could occur on the following Ievels: ( 1) redueing the mathematical variability of the data by counting more plaques per animal, (2) reducing the biological uncertainty of the data by increasing the number of animals per group, (3) lowering the detection Iimit by further lengthening the exposure period. In addition, the creation of new transgenic lineages and comparison of their inherent sensitivities, currently progrcssing in several Iabs, could Iead to better systems.
Mutagenicity assays using transgenic animals offer new promise in the testing of chemieals for mutagenic activity in vivo in an organ-speeific manner. lt is to be hoped that the sensitivity of the assays can be sufficiently inereased in the future that they will be useful not only for mechanistic sturlies at clearly carcinogenic doses, but also allow investigations at low dose Ievels.
